$64.47
-0.13[-0.20%]
At close: May 3
$64.47
0[0.00%]
After Hours: 4:17PM EDT
Alpine Immune Sciences
(NASDAQ:ALPN)Latest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)
Alpine Immune Sciences Stock (NASDAQ: ALPN)
Categories: All
Friday, April 26, 2024
Tuesday, April 16, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
- Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential ImpactVandana Singh - Apr 11, 2024, 2:47PM
- Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?Piero Cingari - Apr 11, 2024, 2:13PM
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 11, 2024, 1:33PM
- 12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga Insights - Apr 11, 2024, 12:31PM
- Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Apr 11, 2024, 10:01AM
- Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine ImmuneVandana Singh - Apr 11, 2024, 9:01AM
- Wedbush Downgrades Alpine Immune Sciences to NeutralBenzinga Newsdesk - Apr 11, 2024, 8:18AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Apr 11, 2024, 8:10AM
- Wolfe Research Downgrades Alpine Immune Sciences to Peer PerformBenzinga Newsdesk - Apr 11, 2024, 8:02AM
- Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'Shanthi Rexaline - Apr 11, 2024, 7:27AM
- Alpine Immune Sciences shares are trading higher after Vertex entered into an agreement to acquire the company.Benzinga Newsdesk - Apr 11, 2024, 7:11AM
- RBC Capital Downgrades Alpine Immune Sciences to Sector Perform, Raises Price Target to $65Benzinga Newsdesk - Apr 11, 2024, 6:56AM
- Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 11, 2024, 6:14AM
- Morgan Stanley Downgrades Alpine Immune Sciences to Equal-Weight, Raises Price Target to $65Benzinga Newsdesk - Apr 11, 2024, 5:46AM
Wednesday, April 10, 2024
- Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars TodayBenzinga Neuro - Apr 10, 2024, 10:19PM
- Alpine Immune Sciences shares are trading higher after Vertex entered into an agreement to acquire the company.Benzinga Newsdesk - Apr 10, 2024, 4:39PM
- Alpine Immune Sciences Shares Resumed TradeBenzinga Newsdesk - Apr 10, 2024, 4:31PM
- Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Apr 10, 2024, 4:25PM
- Alpine Immune Sciences Reports Updated Clinical Data From Povetacicept In IgA NephropathyBenzinga Newsdesk - Apr 10, 2024, 4:16PM
- Vertex Subsidiary To Commence Cash Tender Offer To Purchase All Outstanding Shares Of Alpine Common StockBenzinga Newsdesk - Apr 10, 2024, 4:05PM
- Vertex Enters Into Agreement To Acquire Alpine Immune Sciences For $65 Per Share Or Approximately $4.9B In CashBenzinga Newsdesk - Apr 10, 2024, 4:02PM
- Trading Halt: Halted at 4:00:30 p.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Apr 10, 2024, 4:00PM
- Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?Vandana Singh - Apr 10, 2024, 3:07PM
- Alpine Immune shares are trading higher following a report suggesting the company is weighing options including a potential sale after seeing takeover interest.Benzinga Newsdesk - Apr 10, 2024, 1:27PM
- Watching Vera Therapeutics; Traders Circulating Share Price Moved Higher In Sympathy With Alpine Immune Report Suggesting The Co Is Weighing Options After Takeover InterestBenzinga Newsdesk - Apr 10, 2024, 12:53PM
- 'Alpine Immune Is Said To Weigh Options After Takeover Interest' - BNN BloombergBenzinga Newsdesk - Apr 10, 2024, 12:40PM
Tuesday, April 09, 2024
- Navigating 8 Analyst Ratings For Alpine Immune SciencesBenzinga Insights - Apr 9, 2024, 9:00AM
- Alpine Immune Sciences shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and $55 price target.Benzinga Newsdesk - Apr 9, 2024, 8:27AM
- Guggenheim Initiates Coverage On Alpine Immune Sciences with Buy Rating, Announces Price Target of $55Benzinga Newsdesk - Apr 9, 2024, 7:01AM
Thursday, April 04, 2024
Monday, April 01, 2024
Thursday, March 21, 2024
Tuesday, March 19, 2024
- Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 19, 2024, 1:48PM
- Alpine Immune Sciences Analysts Boost Their Forecasts After Q4 EarningsAvi Kapoor - Mar 19, 2024, 10:35AM
- Alpine Immune Sciences shares are trading higher after the company reported better-than-expected Q4 financial results. Also, multiple firms raised their respective price targets on the stock.Benzinga Newsdesk - Mar 19, 2024, 10:20AM
- Morgan Stanley Maintains Overweight on Alpine Immune Sciences, Raises Price Target to $47Benzinga Newsdesk - Mar 19, 2024, 10:18AM
- National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Mar 19, 2024, 10:03AM
- Evaluating Alpine Immune Sciences: Insights From 6 Financial AnalystsBenzinga Insights - Mar 19, 2024, 10:01AM
- Wedbush Reiterates Outperform on Alpine Immune Sciences, Maintains $47 Price TargetBenzinga Newsdesk - Mar 19, 2024, 9:11AM
- Oppenheimer Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $44Benzinga Newsdesk - Mar 19, 2024, 8:38AM
- HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Raises Price Target to $50Benzinga Newsdesk - Mar 19, 2024, 6:29AM
Monday, March 18, 2024
- Recap: Alpine Immune Sciences Q4 EarningsBenzinga Insights - Mar 18, 2024, 4:50PM
- Alpine Immune Sciences Q4 2023 GAAP EPS $0.15 Beats $(0.29) Estimate, Sales $30.853M Beat $9.104M EstimateBenzinga Newsdesk - Mar 18, 2024, 4:47PM
- Earnings Scheduled For March 18, 2024Benzinga Insights - Mar 18, 2024, 5:57AM